S

Sanofi

Global pharma company; vaccines and R&D

HSE Manager

Full-TimePosted on 10/21/2026Deadline 11/9/26
CA$102.6k - CA$152.6k
Senior
Bachelor's, Master's
Toronto, ON, Canada
In PersonOffice-based in Canada with regular field visits; approximately 30–40% travel across Canada.
Facilities OperationsEnvironmental Health & Safety

About the job

Requirements
  • A bachelor's degree in occupational health and safety, Environmental Science, Sciences, Engineering, or a related field.
  • At least 3 years in an HSE leadership or management role.
  • A minimum of 5–8 years of progressive HSE experience.
  • Strong, current knowledge of Canadian federal and provincial HSE and environmental regulations.
  • Proven experience managing CEPA declarations, data submissions, and regulatory reporting.
  • Solid knowledge of environmental regulatory matters, with the technical understanding required to accurately manage and interpret CEPA-related reporting.
  • Familiarity with the Canadian federal and provincial HSE regulatory framework, environmental management systems, occupational health and safety management systems, risk assessment and hazard identification methodologies, incident investigation and root cause analysis, behavioral safety programs, road safety management and fleet safety standards, HSE data analytics and performance reporting, emergency response planning and crisis management, sustainability and environmental reporting, ergonomics and workplace wellness programs, and mental health and psychological safety in the workplace.
  • Ability to conduct site inspections, safety audits, and field observations.
  • Occasional after-hours availability for incident response or emergency situations.
Responsibilities
  • Develop and continuously evolve the HSE strategy for Commercial Operations and Digital HUB, aligned with global standards and Canadian regulations.
  • Lead governance frameworks, performance reporting, and executive engagement, and represent HSE on the Commercial Operations Leadership Team.
  • Ensure proactive compliance with Canadian federal and provincial HSE legislation, including permits, licenses, and mandatory reporting.
  • Own and submit CEPA declarations and data on the organization's behalf, maintaining the accuracy, completeness, and timeliness of the CEPA database.
  • Manage programs covering waste, air emissions, water, hazardous materials, and sustainability reporting; lead impact assessments and regulatory submissions; and build relationships with environmental and health authorities.
  • Establish HSE standards for Commercial Operations and Digital HUB sites, including ergonomic programs, mental health and psychological safety initiatives, and facility safety, emergency preparedness, and business continuity plans.
  • Champion Leading Safety principles through visible leadership, coaching, safety observations, near-miss reporting, and engagement at all organizational levels.
  • Develop and execute a road safety program for commercial fleet and field teams, covering driver behavior, vehicle standards, journey management, and fatigue risk.
  • Conduct HSE risk assessments across activities, track mitigation measures, and lead incident investigations using structured root cause methodologies such as TapRooT and 5-Why, with shared learnings and corrective actions.
  • Track, analyze, and report HSE metrics and key performance indicators to leadership, manage the incident reporting system, and ensure timely regulatory notifications.
  • Travel approximately 30–40% across Canada and make regular field visits to commercial locations and Digital HUB sites.
Desired Qualifications
  • A master's degree in a relevant discipline.
  • Experience in commercial, office, or non-manufacturing HSE environments.
  • Experience supporting digital, technology, or knowledge-based work environments.
  • A proven track record in road safety programs for field-based commercial teams.
  • A recognized designation such as CRSP, CIH, CSP, or equivalent.
  • Familiarity with ESG and sustainability reporting frameworks.
  • Bilingual English/French ability is strongly preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...